Vivus And Oreixigen Have Too Many Problems For Investors, RBC's Simeonidis Claims
February 29, 2016 at 10:08 AM EST
RBC Capital Markets’ Simos Simeonidis downgraded the ratings for Orexigen Therapeutics, Inc (NASDAQ: OREX) and VIVUS, Inc. ...
